NCT04152629View on ClinicalTrials.gov

Real World Evidence of the Efficacy and Safety of FOQUEST

PHASE4CompletedINTERVENTIONAL
Enrollment

257

Participants

Timeline

Start Date

September 19, 2019

Primary Completion Date

July 9, 2021

Study Completion Date

July 9, 2021

Conditions
Attention Deficit-Hyperactivity Disorder
Interventions
DRUG

Methylphenidate Hydrochloride

CR Methylphenidate Hydrochloride given once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg or 100 mg)

DRUG

Lisdexamfetamine Dimesylate

Lisdexamfetamine Dimesylate given once daily (10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg)

Trial Locations (12)

T2N 4Z6

Matheson Centre for Mental Health Research & Education, University of Calgary, Calgary

V3N 3N4

Adult ADHD Centeres at Pacific Coast Recovery Care, Burnaby

V7T 1C5

Medical Arts Health Research Group, Burnaby

L1Z 0M1

The Kids Clinic Inc., Ajax

N7L 1C1

Chatham-Kent Clinical Trials Research Centre, Chatham

M9V 4C2

Pediatric Institute of Excellence, Etobicoke

P3E 5J1

Health Sciences North, Greater Sudbury

K2G1W2

Center for Pediatric Excellence, Ottawa

N8X 4X9

ADDClinic Windsor, Windsor

G1G 3Y8

Recherche Clinique Sigma Inc, Québec

G2J 0C4

Alpha recherche clinique, Québec

G3K 2P8

Alpha recherche clinique, Québec

All Listed Sponsors
lead

Purdue Pharma, Canada

INDUSTRY

NCT04152629 - Real World Evidence of the Efficacy and Safety of FOQUEST | Biotech Hunter | Biotech Hunter